Circulating miRNA analysis with NGS

 
Oct 23, 2017 1:00 PM–2:00 PM (EDT)
Duration: 1hrs
Circulating RNA can serve as a powerful biomarker for patient stratification and assessment of overall health and prognosis. In this webinar, we will focus on using next-generation sequencing (NGS) for identification of miRNA and mRNAs from biofluids, including best practices for designing and executing a successful experiment.

While RNA is vulnerable to degradation in serum/plasma due to the abundance of RNases and other degrading enzymes, RNA (including mRNA and miRNA) is protected within exosomes and other types of vesicles. Enrichment of exosomes from biofluids provides a supply of RNA biomarkers that can be profiled by NGS and further verified using targeted sequencing or qPCR.

In this webinar, we will show you how QIAGEN’s QIAseq miRNA Library Kit, with is based on the use of Unique Molecular Index (UMI) technology, gives researchers several advantages compared to other small RNA sequencing kits. The QIAseq miRNA Library Kit delivers a gel-free workflow and requires as little as 1 ng of total RNA as input. Its proprietary chemistry minimizes ligation bias and increases the number of miRNA reads by actively blocking irrelevant, contaminating side products and RNAs. Other kits on the market may suggest a gel-free workflow and reduce ligation bias, but their protocols and methods often fall short on delivering these promises. With the inclusion of UMIs in the QIAseq miRNA Library Kit, you can be sure that you have sequenced deep enough to cover the entire library and PCR without sequencing bias and errors.

In addition, we will address workflows for exosome mRNA discovery using stranded RNA-seq and subsequent verification using targeted RNA-seq. QIAGEN’s exosome RNA discovery pipeline starts with a global view of the expressed RNA which is accurately identified using the QIAGEN Biomedical Workbench’s tunable algorithm and verified using QIAseq Targeted RNA Panels. These targeted panels employ UMIs to ensure accurate quantification and adequate sequencing depth for each sample you run.

Join the webinar to hear what the RNA experts have to say about the ‘next generation’ of sequencing-based workflows for biomarker detection and verification!

Jonathan Shaffer

Jonathan M. Shaffer
Dr. Shaffer joined QIAGEN in 2009 and has since worked with various technology development groups, the most recent being miRNA technologies. He received his Ph.D. in biochemistry and molecular genetics from the University of Pittsburgh School of Medicine in 2008 where his research focused on determining the mechanisms that regulate non-receptor tyrosine kinase expression and activity. Dr. Shaffer did his postdoctoral training at SABiosciences Corporation, now part of QIAGEN. Currently, Dr. Shaffer is a Scientist in R&D at QIAGEN.